

## **COMPLETION OF CHM 2101 VIRAL VECTOR MANUFACTURING SUPPORTING INITIATION OF PHASE 1 CLINICAL PROGRAM**

- Completion of manufacturing and quality release of viral vector to support the Phase 1A clinical trial for CHM 2101
- Viral vector is the backbone of CAR T cell therapy manufacturing, making this a critical milestone in advancing CHM 2101 towards the clinic

Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), a clinical stage cell therapy company and an Australian leader in cell therapy, is pleased to announce the completion of the manufacturing and quality release for CHM 2101 viral vector, a key milestone in advancing CHM 2101 towards the clinic.

CHM 2101 is a first in class, 3<sup>rd</sup> generation autologous CAR T cell therapy invented at the world-renowned cell therapy centre, the University of Pennsylvania. Preclinical evidence for CHM 2101 was published in March 2022 in Nature Cancer, with the data demonstrating strong evidence of efficacy with complete eradication of eight different types of gastrointestinal cancers with no relapse or toxicity. Chimeric is currently focused on advancing CHM 2101 towards a phase 1A clinical trial in gastrointestinal and neuroendocrine tumours.

One of the most challenging and critical components of cell therapy technical operations is the timely manufacturing and release of viral vector. Viral vector is considered the backbone for the manufacture of a CAR T cell therapy as it holds the genetic engineering instructions. A current shortage of vector manufacturing capacity has significantly delayed other cell therapy company development programs, as well as challenging commercial manufacturers.

Given these difficulties this is a critical milestone for Chimeric in supporting the advancement of the Phase 1 clinical program for CHM 2101.

“Vector supply continues to significantly challenge the cell therapy industry with current backlogs of more than a year to access vector manufacturing,” said Chimeric CEO and Managing Director Jennifer Chow. “Securing vector supply for the CHM 2101 Phase 1A clinical trial marks a significant milestone for advancing CHM 2101 towards the clinic and patients that need novel therapies to treat advanced gastrointestinal and neuroendocrine tumours.”

For personal use only



## ABOUT CHIMERIC THERAPEUTICS

Chimeric Therapeutics, a clinical stage cell therapy company and an Australian leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer. We believe that cellular therapies have the promise to cure cancer, not just delay disease progression.

To bring that promise to life for more patients, Chimeric's world class team of cell therapy pioneers and experts is focused on the discovery, development, and commercialization of the most innovative and promising cell therapies.

CHM 1101 (CLTX CAR T) is a novel and promising CAR T therapy developed for the treatment of patients with solid tumours. CHM 1101 is currently being studied in a phase 1 clinical trial in recurrent / progressive glioblastoma. Initial positive data has been presented on patients treated in the first two dose levels of the trial. Additional work is being undertaken to expand CLTX to additional solid tumours, beginning with metastatic melanoma.

CHM 2101 (CDH17 CAR T) is a novel, 3rd generation CDH17 CAR T invented at the world-renowned cell therapy centre, the University of Pennsylvania. Preclinical evidence for CHM 2101 was published in March 2022 in Nature Cancer. CHM 2101 (CDH17 CAR T) is currently in preclinical development with a planned phase 1 clinical trial in gastrointestinal tumours.

CHM 0201 (CORE-NK platform) is a clinically validated, off the shelf natural killer (NK) cell platform. Data from the complete phase 1 clinical trial was published in March 2022, demonstrating safety and efficacy in blood cancers and solid tumours. Based on the promising activity signal demonstrated in that trial, an additional Phase1B clinical trial investigating CHM 0201 in combination with IL2 and Vactosertib is now underway. From the CHM 0201 platform, Chimeric has initiated development of four new next generation NK and CAR NK assets with plans for phase 1 clinical trials in solid tumours and blood cancers.

Chimeric Therapeutics continues to be actively engaged in further developing its oncology pipeline with new and novel cell therapy assets that will bring the promise of cell therapy to life for more patients with cancer.

Authorised on behalf of the Chimeric Therapeutics board of directors by Chairman Paul Hopper.

For personal use only



## CONTACT

### Investors

Jennifer Chow  
Chief Executive Officer and Managing Director  
Chimeric Therapeutics  
T: + 1 9087238387  
E: [jchow@chimerictherapeutics.com](mailto:jchow@chimerictherapeutics.com)  
W: [www.chimerictherapeutics.com](http://www.chimerictherapeutics.com)

Paul Hopper  
Executive Chairman  
Chimeric Therapeutics  
T: + 61 406 671 515  
E: [paulhopper@lifescienceportfolio.com](mailto:paulhopper@lifescienceportfolio.com)

### Media

Matthew Wright  
NWR Communications  
P: +61 451 896 420  
E: [matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)

For personal use only